Cleo Diagnostics is drawing attention to the critical need for earlier ovarian cancer detection during Ovarian Cancer Awareness Month in February. The company emphasizes the urgent requirement for more accurate and early detection methods for this deadly disease that affects women. Ovarian cancer is notoriously difficult to diagnose in its early stages due to vague and non-specific symptoms that are often mistaken for less serious conditions. Currently, there is no validated diagnostic test for ovarian cancer, and confirmation is typically only achieved after invasive surgery. As a result, many women are diagnosed when the disease has already progressed, limiting treatment options and significantly worsening outcomes. The consequences of delayed diagnosis are stark, with over half of women diagnosed with ovarian cancer dying within five years, a mortality rate more than six times higher than that of breast cancer. Cleo Diagnostics is addressing this gap through the development of a simple blood test designed to support earlier assessment of ovarian cancer and improve outcomes for women globally. The test is underpinned by more than 15 years of research and development, centered on the discovery of the novel biomarker CXCL10, which has demonstrated superior performance compared with the current standard of care. The company is progressing toward its first commercial market, with a submission to the US Food and Drug Administration anticipated later this year. Dayna Louca, Head of Corporate Development at Cleo Diagnostics, highlights the significance of Ovarian Cancer Awareness Month, emphasizing the campaign's role in reminding us of the challenges associated with early detection and the critical role diagnostics play in improving survival outcomes. She believes that Cleo's ovarian cancer blood test has the potential to fundamentally change the detection landscape, helping to deliver earlier diagnoses and better health outcomes for women worldwide.
